



DIETARY REFERENCE INTAKES

FOR

***Water, Potassium,
Sodium, Chloride,
and Sulfate***

Panel on Dietary Reference Intakes for Electrolytes and Water

Standing Committee on the Scientific Evaluation of Dietary
Reference Intakes

Food and Nutrition Board

INSTITUTE OF MEDICINE
OF THE NATIONAL ACADEMIES

THE NATIONAL ACADEMIES PRESS
Washington, D.C.
www.nap.edu

THE NATIONAL ACADEMIES PRESS 500 Fifth Street, N.W. Washington, DC 20001

NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. The members of the committee responsible for the report were chosen for their special competences and with regard for appropriate balance.

This study was supported by a contract between the National Academy of Sciences and the U.S. Department of Health and Human Services' Office of Disease Prevention and Health Promotion, Contract No. 282-96-0033, T03; the National Heart, Lung, and Blood Institute of the National Institutes of Health; the U.S. Environmental Protection Agency; the U.S. Department of Agriculture; Health Canada; the Institute of Medicine; the Dietary Reference Intakes Private Foundation Fund—International Life Sciences Institute-North America and the Dannon Institute; and the Dietary Reference Intakes Corporate Donors' Fund. Contributors to the Fund have included Roche Vitamins, M&M/Mars, Mead Johnson Nutritionals, and the Nabisco Foods Group. Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the views of the organizations or agencies that provided support for the project.

Library of Congress Cataloging-in-Publication Data

Institute of Medicine (U.S.). Panel on Dietary Reference Intakes for Electrolytes and Water. Dietary reference intakes for water, potassium, sodium, chloride, and sulfate / Panel on Dietary Reference Intakes for Electrolytes and Water, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board.

p. ; cm.

Includes bibliographical references and index.

ISBN 0-309-09158-6 (hardcover) — ISBN 0-309-09169-1 (pbk.) — ISBN 0-309-53049-0 (PDF) 1. Diet. 2. Nutrition.

[DNLM: 1. Nutritional Requirements—Canada. 2. Nutritional Requirements—United States. 3. Electrolytes—Canada. 4. Electrolytes—United States. 5. Reference Values—Canada. 6. Reference Values—United States. 7. Water—Canada. 8. Water—United States.] I. Title.

TX551.I59 2004

613.2—dc22

2004028191

Additional copies of this report are available from the National Academies Press, 500 Fifth Street, N.W., Lockbox 285, Washington, DC 20055; (800) 624-6242 or (202) 334-3313 (in the Washington metropolitan area); Internet, <http://www.nap.edu>.

For more information about the Institute of Medicine, visit the IOM home page at: www.iom.edu.

Copyright 2005 by the National Academy of Sciences. All rights reserved.

Printed in the United States of America.

The serpent has been a symbol of long life, healing, and knowledge among almost all cultures and religions since the beginning of recorded history. The serpent adopted as a logo-type by the Institute of Medicine is a relief carving from ancient Greece, now held by the Staatliche Museen in Berlin.

Contents

SUMMARY	1
1 INTRODUCTION TO DIETARY REFERENCE INTAKES	21
What Are Dietary Reference Intakes?, 21	
Categories of Dietary Reference Intakes, 22	
Parameters for Dietary Reference Intakes, 29	
Summary, 35	
References, 35	
2 OVERVIEW AND METHODS	37
Summary, 37	
Background, 37	
Methodological Considerations, 38	
Estimates of Nutrient Intake, 46	
Dietary Intakes in the United States and Canada, 47	
References, 48	
3 A MODEL FOR THE DEVELOPMENT OF TOLERABLE UPPER INTAKE LEVELS	50
Background, 50	
A Model for the Derivation of Tolerable Upper Intake Levels, 52	
Risk Assessment and Food Safety, 52	
Application of the Risk Assessment Model to Nutrients, 57	

Steps in the Development of the Tolerable Upper Intake Level, 61 Intake Assessment, 70 Risk Characterization, 70 References, 72	7	SU Su Ba Inc
4 WATER Summary, 73 Background Information, 74 Body Water, 75 Methods for Estimating Water Requirements, 86 Methods for Estimating Hydration Status, 90 Factors Affecting Water Requirements, 127 Findings by Life Stage and Gender Group, 140 Intake of Water, 157 Adverse Effects of Overconsumption, 161 Research Recommendations, 165 References, 166	73	Fa Fi In Ac Re Re
5 POTASSIUM Summary, 186 Background Information, 188 Indicators Considered for Estimating the Requirement for Potassium, 190 Factors Affecting Potassium Requirements, 225 Findings by Life Stage and Gender Group, 231 Intake of Potassium, 242 Adverse Effects of Overconsumption, 247 Research Recommendations, 254 References, 255	186	8 AF FC Ov As As Pl Pl Ni Su Re
6 SODIUM AND CHLORIDE Summary, 269 Background Information, 272 Indicators Considered for Estimating the Requirements for Sodium and Chloride, 275 Factors Affecting Sodium and Chloride Requirements, 293 Findings by Life Stage and Gender Group, 301 Intake of Sodium, 318 Adverse Effects of Overconsumption, 323 Research Recommendations, 395 References, 397	269	9 A Aj M Tl APPE A G B O C R D Pi E U H E U F C F by G T G U th Si

CONTENTS

xvii

7	SULFATE	424
	Summary, 424	
	Background Information, 425	
	Indicators Considered for Estimating the Requirement for Sulfate, 429	
73	Factors Affecting Sulfate Requirements, 429	
	Findings by Life Stage and Gender Group, 430	
	Intake of Sulfate, 430	
	Adverse Effects of Overconsumption, 433	
	Research Recommendations, 433	
	References, 433	
186	8 APPLICATIONS OF DIETARY REFERENCE INTAKES FOR ELECTROLYTES AND WATER	449
	Overview, 449	
	Assessing Nutrient Intakes of Individuals, 450	
	Assessing Nutrient Intakes of Groups, 453	
	Planning Nutrient Intakes of Individuals, 455	
	Planning Nutrient Intakes of Groups, 456	
	Nutrient-Specific Considerations, 456	
	Summary, 461	
	References, 462	
269	9 A RESEARCH AGENDA	465
	Approach, 465	
	Major Knowledge Gaps, 466	
	The Research Agenda, 468	
	APPENDIXES	
	A Glossary and Acronyms	471
	B Origin and Framework of the Development of Dietary Reference Intakes	477
	C Predictions of Daily Water and Sodium Requirements	485
	D U.S. Dietary Intake Data from the Third National Health and Nutrition Examination Survey, 1988–1994	494
	E U.S. Dietary Intake Data for Water and Weaning Foods from the Continuing Survey of Food Intakes by Individuals, 1994–1996, 1998	518
	F Canadian Dietary Intake Data for Adults from Ten Provinces, 1990–1997	527
	G U.S. Water Intake and Serum Osmolality Data from the Third National Health and Nutrition Examination Survey, 1988–1994	534

H	U.S. Total Water Intake Data by Frequency of Leisure Time Activity from the Third National Health and Nutrition Examination Survey, 1988–1994	537
I	Dose-Response Effects of Sodium Intake on Blood Pressure	546
J	U.S. Serum Electrolyte Concentration Data from the Third National Health and Nutrition Examination Survey, 1988–1994	558
K	Options for Dealing with Uncertainties	564
L	Acknowledgments	569
M	Biographical Sketches of Panel Members	572
INDEX		577
SUMMARY TABLES, DIETARY REFERENCE INTAKES		
	Recommended Intakes for Individuals, Vitamins	606
	Recommended Intakes for Individuals, Elements	608
	Recommended Intakes for Individuals, Total Water and Macronutrients	610
	Acceptable Macronutrient Distribution Ranges	611
	Additional Macronutrient Recommendations	611
	Tolerable Upper Intake Levels (UL), Vitamins	612
	Tolerable Upper Intake Levels (UL), Elements	614
	Estimated Average Requirements for Groups	616

Index

A

Acetaminophen, 428
Acid-base balance, 8, 136, 186-187, 189-190, 194, 221, 224-225, 228, 229, 240
Addison's disease, 243
Adenosine triphosphate, 426
Adequate Intakes (AIs). *See also individual nutrients*
applicable population, 22
criteria used to derive, 6-7, 10, 12, 22, 28-29
defined, 3, 22, 26-27, 471
derivation of, 28-29, 30, 43-46, 140, 452, 454, 456-457
extrapolation between other age groups, 27
indicators used to set, 3-4, 28-29
for labeling, 456
RDA compared, 23, 27
uncertainty in, 27
uses, 18-19, 27, 144, 452, 453-456, 462-463
Adipose tissue, water content of, 75
Adolescents, ages 9 through 18 years
ages 9 through 13 years, 31-32, 143, 306

ages 14 through 18 years, 31-32, 143-144, 152, 239, 306, 382-383, 540-545
AIs, 27, 142-143, 232-234, 306-307, 316
blood pressure, 232-233
cystic fibrosis, 137, 138
energy intakes, 306
lactation, 153, 316, 383
physical activity, 540-545
potassium, 232-234, 239, 240, 249, 252
pregnancy, 152, 239, 316, 382-383
sodium and chloride, 306-307, 316, 382-383, 385-387
ULs, 373, 376-381, 385-387
water, 90, 142-144, 152, 153, 155-157, 159-160, 540-545
weights and heights, reference, 482, 483
Adrenal insufficiency, 253
Adults, ages 19 through 50 years
active, 154-155
ages 19 through 30 years, 32, 145, 148, 528-533, 540-545
ages 31 through 50 years, 32, 145, 148, 528-533, 540-545
AIs, 32, 144-147, 234-235, 307-310

- blood pressure, 234
 Body Mass Index, 483
 bone mass, peak, 32
 bone mineral density, 234
 cardiovascular disease, 234
 dietary intakes, 86, 307-308, 309, 320
 energy metabolism, 32, 386
 extrapolation of data to infants and children, 45, 233, 386
 extrapolation of data to older adults, 45
 heat stress, 307
 insulin resistance, 307
 kidney stones, 234
 lactation, 153, 316
 lipid levels, 308
 physical activity, 103, 154-155, 308, 540-545
 potassium, 32, 191, 225, 226, 228, 234-235, 245, 249, 323, 530-531
 pregnancy, 152, 316
 pulmonary function, 225
 renal function, 148
 sodium and chloride, 11, 32, 148, 234, 270, 271, 276, 281-282, 307-310, 316, 320, 322, 323, 373, 376-381, 382-383, 532-533
 special considerations, 144, 154-155, 308
 stroke, 234
 sulfate, 428, 433-436, 440-441
 supplements, 249
 thermoregulation, 83
 ULs, 249, 373, 386-381
 urine osmolalities, 82
 water, 5-6, 75, 82, 83, 86, 87-88, 90, 92-93, 103, 144-147, 148, 153, 154-155, 157-158, 159-160, 161, 528-529, 540-545
 weights and heights, reference, 482
 Adults, ages 51 through 70+ years
 ages 51 through 70 years, 32-33, 150, 528-533, 540-545
 ages 71 years and older, 32-33, 150, 528-533, 540-545
 AIs, 45-46, 147-150, 236-237, 310-313
 alcohol, 148
 bioavailability of nutrients, 32
 blood pressure, 46, 237, 311-312, 380
 cognitive function and motor control, 105-108
 dehydration, 148, 149
 derivation of DRIs for, 32
 diuretics, 299
 energy expenditure, 33
 energy intakes, 312
 extrapolation of data from younger adults, 45-46, 237, 312
 hyperinsulinemia, 236-237
 hyperkalemia, 188, 237
 hypernatremia, 149
 hypertension, 283
 hyponatremia, 299
 physical activity, 540-545
 plasma renin activity, 283, 311
 potassium, 46, 188, 213, 236-237, 323, 530-531
 renal function, 32, 99, 147-149, 236, 310-312
 reserve capacity and functioning, 32
 salt sensitivity, 311
 sodium and chloride, 11-12, 45-46, 148, 270, 271, 280-281, 283, 299, 301, 310-313, 323, 381-382, 380, 381-382, 532-533
 stroke, 150, 213
 supplements
 thirst, 149-150
 ULs, 381-382
 urine osmolalities, 82, 147, 149
 water, 82, 92-93, 99, 147-150, 159-160, 161, 310, 528-529, 540-545
 Adverse effects, 50-51, 66, 70, 471
 African Americans
 blood pressure, 187, 202-203, 212, 230-231, 234, 380, 387, 393
 hydration of fat-free mass, 76-77
 hypertension, 195-196, 218, 334-335, 340-341, 346, 347
 left ventricular hypertrophy, 366
 plasma renin activity, 283, 284-287

- potassium, 9, 187, 195-196, 202-203, 212, 234, 245, 247, 334-335, 508-509
pubertal development, 32
salt sensitivity, 195-196, 230-231, 387
sodium, 202-203, 212, 334-335, 340-341, 346, 347, 514-515
water consumption, 141
- Age. *See also* Adolescents; Adults; Children; Infants; Life-stage groups; Toddlers
and hydration of fat-free mass, 76-77
- Alcohol, 7, 123, 134-135, 148, 323, 329, 354-355, 458
- Aldosterone, 189, 194, 238-239, 243, 277, 281, 291, 311, 314, 315, 393
- Aldosteronism, 238-239, 314, 393
- Alpha-adrenergic agonists, 243, 381
- Altitude exposure, 80, 132-133
- American Academy of Pediatrics, 30, 43, 44
- American Water Works Association, 442
- Amiloride, 227, 243
- Amino acids, sulfur-containing, 187, 189, 244, 425, 427, 429, 434-435
- 5-Aminosalicylic acid, 440
- Analgesics, 139
- Angiotensin converting enzyme inhibitor drug therapy, 188, 241-242, 243, 283
- Angiotensin gene, 394
- Angiotensin II, 111, 273, 274, 281, 311, 315
receptor blocker, 392
- Animal studies
cardiovascular disease, 357-358
of dehydration, 79, 111, 120-121
extrapolation of data from, 53, 65, 68, 564, 565
potassium, 213, 236
pregnant animals, 437-438
relevance of, 38, 61-62, 63-64
sodium and chloride, 301, 302-303, 357-358, 373
- sulfate, 437-438
young animals, 438
- Antibiotics, 139
- Anticholinergic drugs, 139
- Antidepressants, 139
- Arginine vasopressin, 92, 94, 104, 111, 134, 135, 139, 140, 148, 149, 151, 152, 163, 315
- Asians
sodium intake, 358
water requirements, 90
- Asthma, 372, 377
- Atherosclerosis, 386
- Athletes. *See also* Physical exercise and activity
body weight changes, 102
carbohydrate loading, 102
dehydration, 121, 125
potassium balance, 226-227
rapid weight loss, 121, 125
sodium balance, 317
sweating rates, 127, 226
total body water, 78
urine color chart, 99
water consumption, 127, 162, 163
- Atrial natriuretic peptide, 139, 148, 273, 315

B

- Bacteria, sulfate-reducing, 439
- Balance studies
chloride, 280
defined, 39
potassium, 191-192, 193
pregnant women, 314
sodium and chloride, 275-281, 301-302, 314
water, 86-89, 93, 140, 142
- Bartter's syndrome, 239, 303
- Beta-adrenergic blockade, 236, 237, 243
- Bicarbonate, 190, 194. *See also* Potassium bicarbonate
precursors, 8, 186, 188, 240-241, 242, 244

- Bioavailability of nutrients
defined, 60
factors affecting, 60-61
from infant formula, 30
nutrient-nutrient interactions and,
60
and risk assessment, 60-61, 66
sulfate, 431
from supplements, 22, 60-61
- Bioelectric impedance analysis, 91-92, 151
- Biomarkers of disease, 39
- Biotin, 426
- Bladder cancer, 124-125
- Bladder lesions, 164
- Blood clots, 126
- Blood lipid concentrations, 12, 270, 283, 292, 294-295, 308
- Blood pressure. *See also* Hypertension
calcium and, 388, 389, 390
and cardiovascular disease, 272, 323-325, 366, 377, 378, 379, 380, 385, 387
DASH diet and, 292, 295, 308, 309, 334-335, 346, 347, 348-349, 355, 369, 379, 390, 391, 472, 553-555
diabetes mellitus and, 16, 271, 272, 391-392
elevation in, 286-291
as endpoint, 376-377
epidemiological studies, 197-200, 323-324, 326-329
fruit and vegetable intakes and, 200-201
gender and, 348, 386, 390-391
genetic factors, 16, 271, 393-394
hydration status and, 118-120
interaction of dietary factors and, 388-390
intervention studies, 200-212, 325, 329-351, 546-557
intrinsic variability in, 287-290
longitudinal studies, 385-386
magnesium and, 388, 389, 390
measurement precision, 289, 328, 385
- observational studies, 197-200, 326-329
- plasma renin activity, 283
- potassium and, 8, 9, 38, 186, 187, 194, 195-212, 213, 218, 228, 229, 230-231, 232-233, 234, 235, 237, 239, 241, 298, 330-345, 347, 388, 390
- prehypertension category, 378
- pressor response, 289
- race/ethnicity and, 348, 380, 387, 388
- and renal disease, 16, 271, 272, 325-326, 380, 392
- salt resistant, 287, 292, 388
- salt sensitive, 8, 9, 16, 38, 186, 187, 194, 195-197, 228, 230-231, 234, 235, 271, 287, 311, 380, 381-382, 387-388, 389, 391, 392, 393, 475
- sodium bicarbonate and, 275
- sodium chloride and, 15-16, 195-197, 202-212, 228, 230-231, 270-271, 273, 275, 281-291, 300, 311-312, 323-357, 376-379, 382-394, 395, 546-557
- weight and, 390, 394
- Blood urea nitrogen (BUN), 98-99
BUN:creatinine ratio, 99
- Body Mass Index, 34, 59, 348, 364, 482, 483
- Body water. *See also* Hydration status;
Water consumption
adolescents, 90
adults (19-50 years), 75, 82, 83, 86-87, 90, 92-93
by age and gender group, 77-78
assessment of changes, 90-99; *see also* Hydration status
balance, 92, 93, 100, 140, 142, 154, 367
- bioelectric impedance analysis, 91-92, 151
- children, 75, 90, 142
- determinants, 79-86
- distribution, 78
- exchange, 78-79

- fat-free mass, 75-77, 142, 457
function, 4, 37, 73, 74
hydrogen isotope activity, 89, 91, 142, 151
infants, 75, 90, 140-141
insensible and sweat losses, 83-85, 105, 127, 140, 154, 155-156, 163
metabolic production, 81, 83, 85-86, 102, 140-141
older adults (51+ years), 92-93
pregnancy, 151
respiratory losses, 80-81, 102, 132-133
total, 77-79, 90-99, 142, 163
turnover rates, 78, 89-90, 91, 140, 141, 142, 154
urinary and gastrointestinal losses, 81-83, 102, 105, 135-136, 140
weight and, 77, 78, 86-87
- Bone catabolism, 38, 274
Bone mass, peak, 32
Bone mineral density
 calcium and, 190, 372, 374-375, 377
 fluid intakes and, 126-127
 hypercalciuria and, 372, 374-375
 potassium and, 8, 38, 186, 187, 189, 190, 194, 219-222, 228, 231, 233, 234, 235, 240
 sodium chloride and, 190, 372, 374-375, 377, 395
- Breastfeeding. *See also* Human milk;
 Lactation
 recommendations, 29-30, 43, 384
 and water intakes from weaning foods, 526
- Bronchitis, 372
- C**
- Caffeine, 7, 133-134, 226, 458
Calcium, 33
 and blood pressure, 388, 389, 390
 and bone mineral density, 190, 372, 374-375, 377
 dietary intakes, 309
 in drinking water, 127
- epidemiological studies, 374-377
gender differences, 369
high-protein diet and, 369
intervention studies, 370-371
and kidney stones, 122, 123, 223, 372, 374-377
potassium and, 189, 190, 194, 218, 219, 221, 222, 224, 228, 229, 230, 240
sodium chloride and, 222, 299, 369-372, 374-375, 377, 388, 389
supplements, 299, 389
urinary excretion, 240, 377
urolithiasis, 221-222
- Calcium for Prevention of
 Preeclampsia trial, 245, 322-323
- Canada
 dietary intake data, 48, 187, 245, 320, 394-395, 527-533
 flavor preference in beverages, 103-104
 hypertension prevalence, 351
 potassium intakes, 187, 245
 reference nutrient values, 1, 449, 478
 sulfate standard for drinking water, 442
 water intakes, 6, 74, 160, 528-529
 weights and heights, reference, 482-483
- Canadian National Institute of
 Nutrition, 478
- Canadian Paediatric Society, 29-30, 43, 44
- Carbamazepine, 299
- Carbohydrate, 135, 309. *See also* Low-carbohydrate, high-protein diets
- CARDIA Study, 200-201
- Cardiac arrhythmias, 8, 38, 125-126, 186, 194, 227, 242, 248-249
- CARDIAC Study, 360-361
- Cardiovascular disease
 animal studies, 357-358
 children, 385
 diabetes and, 300
 epidemiological studies, 358-365, 368

- gender differences, 366
 high blood pressure and, 272, 323-325, 357-365, 366, 377, 378, 379, 385, 387; *see also* Hypertension
 intervention studies, 364, 367, 368-369
 left ventricular hypertrophy, 283, 323, 358, 365-369, 377
 mortality, 324, 365
 potassium and, 8, 186, 195, 213-219, 241, 323
 prevention, 213-219
 sodium chloride and, 12, 270, 283, 323-325, 357-365, 377, 378, 379, 385, 387, 395
 Cardiovascular function
 arterial pH, 190, 221
 cold beverages and, 125-126
 heat stress and, 120
 hydration status and, 110, 118-120, 125-126
 long airline flights, 126
 physical exercise and, 119-120
 Caucasians
 blood pressure, 195-196, 202-203, 230-231
 hydration of fat-free mass, 76-77
 potassium, 506-507
 pubertal development, 31
 salt sensitivity, 195-196, 230-231
 sodium, 512-513
 water consumption, 141
 Centers for Disease Control and Prevention, 433, 440
 Central nervous system function, 110
 Cerebroside sulfate, 13
 Children, ages 4 through 8 years, 31.
See also Life-stage groups;
 Toddlers
 active, 155
 AIs, 24, 27, 45, 142-143, 232-233, 306-307
 blood pressure, 232-233
 dehydration, 110
 energy intakes, 306, 386
 extrapolation of data from adults to, 24, 27, 33, 45, 306, 386
 flavor preferences, 103-104
 hypercalcioria, 223
 hypertension, 386
 hyponatremia, 164
 physical activity, 45, 103, 110, 538-539
 potassium, 45, 223, 225, 232-233, 234, 237, 249, 252, 323
 pulmonary function, 225
 sodium and chloride, 45, 103-104, 278-281, 306-307, 323, 385-387
 sweating, 155-156
 UL derivation for, 45, 249, 252, 385-387
 water, 45, 75, 87, 90, 103-104, 142-143, 155-157, 159-160, 164, 538-539
 weights and heights, reference, 33, 482, 483
 Chloride. *See also* Sodium and chloride
 AIs, 12-13, 270, 305, 307, 310, 313, 316
 balance studies, 280
 bicarbonate ratio, 228
 deficiency, 280
 infants, 280, 303
 serum, 562-563
 ULs, 382, 383, 385, 387
 Chlorpropamide, 299, 300
 Chondroitin sulfate, 13, 429, 431, 439
 Chorthalidone, 227, 241
 Chronic diseases
 dehydration and, 122-127, 136-138
 preventive effects of potassium, 194, 213-219
 Citrate excretion, 188, 224-225
 Climate
 cold, 81, 83, 89, 102, 132-133
 and exercise-related dehydration, 108-110, 111
 hot, 81, 82, 83-84, 102, 104, 110, 111, 115, 117, 127, 128-129, 154, 155, 157, 164, 297-298
 and hydration, 81, 82, 132-133, 154
 and potassium, 225-227
 and sodium, 275-276

and sweating rate, 102
and thirst, 104
and urine output, 82, 83
and water consumption, 6, 74, 88,
 89, 90, 132-133, 157, 164
Cognitive function, 32, 105-108, 139,
 150
Colon cancer, 124
Congestive heart failure, 227, 241, 242,
 253, 365
Continuing Survey of Food Intakes by
 Individuals, 47-48, 141, 157, 158,
 231, 232, 233, 304, 306, 312, 320,
 461, 471-472, 518-526
Coronary heart disease, 213, 216-217,
 218, 283, 323, 325, 357-365, 377
Creatinine, 242, 358
Critical endpoint
 blood pressure as, 376-377
 defined, 66
 sodium and chloride, 376-377
Cyclo-oxygenase-2 inhibitors and, 242,
 243
Cysteine, 27, 13, 424, 425, 426, 427,
 429, 432, 439
Cystic fibrosis, 137-138, 163, 300, 303
Cystine, 439

D

D-penicillamine, 430
DASH diet, 292, 295, 308, 309, 334-
 335, 346, 347, 348-349, 355, 369,
 379, 390, 391, 472, 553-555
DASH-Sodium Trial, 308, 346, 347-348,
 350, 391, 461, 472, 553-555
DASH trial, 231, 289-290, 472
Data and database issues
 availability of data, 2-3, 24, 27, 28,
 29, 31, 298, 376, 451
 critical data set, 65
 for dose-response assessment, 65-66,
 373, 376
 for hazard identification, 61-62, 63-
 64
 human studies, 2-3, 65

quality and completeness of, 3, 4,
 13, 27, 41-43, 47, 51, 56, 63-64,
 66, 123, 235, 307, 382, 424, 430,
 441, 467
selection for dose-response
 assessment, 65-66, 373, 376
 sodium and chloride, 373, 376
sulfate, 3, 4, 27
uncertainties in, 53, 56, 57
Death
 hydration status and, 120-121, 161
 hyperkalemia and, 242
Dehydration
 altitude exposure and, 132
 animal studies, 79, 111, 120-121
 and blood clots, 126
 and cardiac arrhythmias, 125-126
 and cardiovascular function, 110,
 118-120, 125-126
and central nervous system
 function, 110
children, 110
and chronic diseases, 122-127, 136-
 138
cognitive performance and motor
 control, 105-108
and death, 120-121
defined, 472
diuretic-induced, 97, 139-140
and gastric emptying rate, 131-132
and heat strain tolerance, 97, 111,
 114-115, 131-132
indicators of, 92-94, 99, 100-101
infants, 384
and metabolic functions, 110
mild diagnosis as hyponatremia, 163
and mitral valve prolapse, 126
and muscular strength, 110, 116-117
and osteoporosis, 126-127
partitioning of water loss, 79
and physical work, 97, 108-110, 112-
 113, 114, 116-117, 163
plasma volume, 97
and renal function, 98, 99, 139, 148,
 152
and thermoregulation, 79, 110, 111

INDEX

- and urinary tract infections, 121-122
 and urine output, 82, 83
 Depletion-repletion studies
 defined, 39
 Desoxycorticosterone, 238, 315
 Diabetes insipidus, 140, 152
 Diabetes mellitus. *See also* Insulin
 and blood pressure, 16, 271, 272, 391-392
 and cardiovascular disease, 300, 380
 and dehydration, 136-137, 139
 and hyperkalemia, 241, 242, 243, 252-253
 and hyporeninemic
 hypoaldosteronism, 301
 sodium and chloride and, 16, 300-301, 380, 391-392
 urine osmolality and, 100, 136
 Diarrhea, 78, 94, 303, 424, 427, 433-438, 440, 441
 Dietary Approaches to Stop Hypertension. *See* DASH diet
 Dietary intakes. *See also* Water consumption
 adjustment of, 47, 48, 450, 453
 assessment of, 79, 326, 450-455
 and bioavailability
 breast-fed infants, 30, 141-142, 526
 calcium, 309
 Canadian, 48, 527-533
 day-to-day variations in, 326, 451, 453
 energy, 45, 46, 452
 food composition databases, 46, 47, 48, 79, 450, 453
 form of, 58, 60
 gender differences, 7, 504-507, 512-517, 530-531
 potassium, 9, 10, 44, 48, 187, 192, 193, 194, 197, 202, 204, 206, 208, 210, 232, 234, 242, 245-247, 309, 504-507, 516-517, 526, 530-531
 race/ethnicity and, 506-509, 512-515
 self-reported, 40, 47, 48, 145, 224, 320, 326, 451
 sodium chloride, 44, 46, 48, 203, 212, 272, 276, 277, 281, 282, 285, 287, 304, 320-323, 330, 332, 334, 336, 338, 340, 342, 344, 347, 394, 395-396, 455, 510-513, 516-517, 526, 532-533
 sources of data, 47-48
 sulfate, 427, 428, 433, 434-435
 uses of data, 450-455
 Dietary Reference Intakes (DRIs)
 applicable population, 22
 assessment applications, 17-19, 450-455
 categories, 21, 22-29; *see also*
 Adequate Intakes; Estimated Average Requirements;
 Recommended Dietary Allowance; Tolerable Upper Intake Levels
 criteria for, 2-4, 6-7, 10, 12, 21, 28-29
 defined, 3, 21-22, 35
 extrapolation from other age groups, 33
 framework, 450, 478-480
 group applications, 18-19, 26, 453-455, 456
 individual applications, 17-19, 451-452, 455-456
 origin, 477-478
 parameters for, 29-34; *see also* Life-stage groups; Reference weights and heights
 planning applications, 455-456
 rationale for, 449
 sources of data, 2-3, 450-451; *see also*
 Methodological considerations
 uses, 17-19, 449-463
 WHO/FAO/WHO approach
 compared, 22
 Dimercaptopropanol, 430
 Diuretics and diuresis
 alcohol, 7, 134-135
 caffeine, 7, 133-134
 and dehydration, 97, 139-140
 and hypochloremia, 299

and hyponatremia, 281, 299
medications, 97, 139, 382
osmotic, 136
plasma volume changes, 97
and potassium, 188, 194-195, 227,
239, 241, 242, 243, 249, 252-253
and sodium chloride, 281, 283, 299,
311, 382
and water intake, 7, 139-140
Dopamine, 381
Dose-response assessment
adolescents, 385-387
adults, 249, 373, 376-381, 440-441
animal data, 61-62, 63
children, 249, 252, 385-387
components and process, 54, 55, 62,
378
critical endpoint, 65-66, 376-377
data quality and completeness, 3
data selection, 65-66, 373, 376
defined, 472
derivation of UL, 65, 68-69, 380-381
infants, 249, 252, 384-385, 441
lactation, 252-253, 382-383
LOAEL/NOAEL identification, 66,
377-379
older adults, 381-382
potassium, 212, 249-254
pregnancy, 252, 382-383
sodium and chloride, 15-16, 345-
346, 373-387, 394, 546-557
special considerations, 68, 69, 442
sulfate, 438, 440-442
uncertainty assessment, 66-68, 379-
380
water, 154-165
Drinking water
bottled water, 318, 440
calcium in, 127
intakes by gender and life-stage, 73,
86, 158, 161, 498-501, 520-523
sulfate in, 13, 425, 430, 432, 433-
435, 436-437, 438, 440, 442-443
taste, 102-104
temperature, 102-104, 135-126

E

Electrolyte balance, 272
Electrolyte-carbohydrate beverages,
126, 226
End-stage renal disease, 139, 253, 325-
326, 377, 442, 459
Endothelial relaxing factor, 274
Energy metabolism, 24, 32, 33, 45, 46,
85-86, 131, 132, 233, 270, 315,
386, 461, 485-493
Environmental factors
water consumption, 4, 74, 88, 89,
90, 127-133, 144
Epidemiological studies. *See also*
Observational studies
analytic studies, 40
blood pressure, 197-200, 323-324,
326-329
bone demineralization prevention,
219, 220-221
calcium, 374-377
cardiovascular disease, 358-365,
368
kidney stone prevention, 222-224
meta-analyses, 323-324
potassium, 197-200, 212, 214-217,
219, 220-221, 222-224, 225, 234
sodium and chloride, 283, 323-324,
326-329, 358, 359, 368, 374-377,
378, 381
Estimated Average Requirements
(EARs)
coefficient of variation, 24
country comparisons
defined, 3, 23-24, 451, 472
derivation of, 3, 24-26, 144, 480-481
method used to set, 24-26, 42, 453
and RDA, 23, 24-26
research recommendations, 466-467
standard deviation, 24, 480
uses, 18-19, 24-26, 42, 451-452, 4
62

Exercise. *See* Physical exercise and activity

Exposure

- acceptable or tolerable, 53
- duration of, 63, 66
- route of, 63, 65, 66

Exposure assessment

- process, 54, 55, 63
- and UL derivation, 57, 70
- water overconsumption, 165

F

Factorial approach, 25, 480-481

Fainting, 118-119

Fat-free mass, 75-77, 142, 457

Fatigue, 106

Fecal

- potassium losses, 189, 191
- sodium losses, 277
- water losses, 135-136, 140

Fetal sulfate requirements, 429-430

Fever, 78, 111, 120-121. *See also* Temperature, core body; Thermoregulation

Fiber, dietary, 135-136, 191, 201, 231, 309

Fire fighters, 154, 317

Food additives, 319

Food and Agriculture Organization, 22, 51, 56

Food sources

- determination of, 48, 22
- potassium, 8-9, 186, 187, 188, 192, 200-204, 212, 242, 244-245, 249
- sodium and chloride, 304, 318-320
- sulfate, 4, 13, 27, 37, 424, 425, 426, 428, 430-433
- water, 5, 502-503, 524-525

Formulas, infant

- bioavailability of nutrients from, 30, 43, 455
- sodium and chloride, 280, 303, 305-306, 306
- sulfate, 301, 302, 303, 305-306, 432

Fortified foods, 28, 51, 58, 59. *See also* Formula, infant

Framingham Heart Study, 365-366

Furosemide, 241, 299, 311

G

Gallstones, 124

Gastric cancer, 372-373, 377, 395

Gastric emptying rate, 131-132

Gastrointestinal

- potassium-related discomfort, 247-249, 252
- water losses, 81-83

Gender differences. *See also* Men; Women

blood pressure, 348, 386, 390-391

body water, 77-78

calcium, 369

cardiovascular disease, 366

physical activity, 538-545

- potassium, 10, 192, 504-509, 516-517, 530-531

puberty onset, 32

serum osmolality, 534-536

- sodium and chloride, 312, 322, 348, 369, 390-391, 510-513, 516-517, 532-533, 560-563

water consumption, 7, 87, 88, 90, 91, 93, 127, 143-144, 145, 147, 150, 154, 155, 159-160, 161, 494-503, 518-525, 528-529, 534-545

Genetic factors, salt-sensitive blood pressure, 16, 271, 393-394

Genetic markers of disease, 39

Gentamycin, 439, 440

Gibbs-Donnan equilibrium, 78

Gitelman's syndrome, 393

Glomerular filtration rate, 148, 149, 152, 241, 253, 315

Glomerulonephritis, 139

Glucosamine sulfate, 428-429, 431

Glucose excretion, 100

Glucose intolerance, 8, 186, 194, 292, 296-297; *see also* Diabetes mellitus

Glutathione, 426, 429, 430

Glycogen
Glycosides
Glycosaminoglycan
Growth hormone
sodium
sulfur
velocity

Hazardous
anions
carbohydrates
coenzymes
data
dehydrogenase
evening primrose oil
hydrogen peroxide
plasma

potassium
sodium
sulfur
water

Health
Health

Glycogen, skeletal muscle, 78, 102
Glycosaminoglycans, 430
Glycosuria, 136, 300
Growth
 sodium chloride and, 301-303
 sulfate and, 427-428, 429-430
 velocity, 29, 31, 32

H

Hazard identification
 animal data, 61-62, 63
 causality, 63, 70
 components of, 54, 55, 62
 data sources, 61-62
 defined, 473
 evaluation process, 62-63
 human studies, 61
 pharmacokinetic and metabolic
 data, 63-64, 69
 potassium, 247-249
 sodium and chloride, 323-373
 sulfate, 433-440
 water, 162-164
Health Canada, 1, 21, 320, 473, 478
Health Professionals Follow-up Study,
 198-199, 214-215, 218, 223, 327
Heat acclimatization, 92, 97, 98, 109,
 114, 115, 127, 129-130, 226, 276,
 277, 296-297, 308
Heat balance, 133
Heat exhaustion, 115
Heat strain tolerance, 89, 97, 111, 114-
 117, 127-132, 485-493
Heat stress, 78, 83, 90, 105, 110, 118,
 120-121, 131, 133, 157, 308
 and potassium, 225-227
Heat stroke, 121
Heliobacter pylori infection, 373
Hematuria, 280
Henderson-Hasselbalch equation, 274
Heparin, 242, 243, 431
High-density lipoprotein cholesterol,
 283, 292, 294-295
Honolulu Heart Study, 213-215, 216
Human feeding studies, 38-39

Human milk
 potassium, 231-232, 239-240
 sodium and chloride, 304, 305, 384
 sulfate, 432
 volume of intake, 30, 43, 141, 231
 water content, 153
Hydration status. *See also* Dehydration;
 Hyperhydration
 and blood pressure, 118-120
 blood urea nitrogen and, 98-99
 and body weight changes, 101-102,
 110, 151
 and cardiovascular disease, 367
 fluid consumption and, 86, 92, 94-
 95, 102
 and health and performance, 105-
 127
 heat acclimatization and, 92, 97, 98
 indicators, 4, 5, 73, 77, 90-91, 122,
 142, 144
 lactation and, 153
 methods for estimating, 90-127
 plasma osmolality, 4, 92-94, 100,
 102, 104, 115, 139, 151-152
 plasma sodium concentration and,
 95-97
 plasma volume changes and, 37, 97-
 98, 102, 104-105, 119, 132, 150,
 151
 pregnancy and, 151-152
 saliva specific gravity and, 100-101
 serum osmolality, 4, 5, 94-95, 135,
 137, 142-143, 148, 534-536
 sodium and chloride and, 94, 95-97,
 296, 301, 310
 thirst and, 86, 102-105, 149-150, 151
 total body water changes, 90-99
 urine indicators, 82-83, 92, 99-101,
 105, 148
 and water consumption, 86, 94-95
Hydrochlorothiazide, 241
Hydrogen, 273
Hydrogen isotope activity, 89, 91, 142,
 151
Hydroxyapatite, 190
Hyperaldosteronism, 280

INDEX

Hypercalciuria, 194, 222, 223, 369
 Hypercapnia, 80
 Hyperchloremia, 302
 Hypercitraturia, 224-225
 Hyperglycemia, 136, 194, 300
 Hyperhydration
 defined, 473
 detection methods, 92
 and heat strain, 115-117
 and performance, 117-118
 and plasma volume, 97
 and sweating, 116
 and urine output, 83, 152
 Hyperinsulinemia, 194, 236-237
 Hyperkalemia, 14, 15, 38, 188, 192,
 195, 237, 241-242, 243, 248-249,
 253, 458, 473
 Hypernatremia, 14, 149, 315, 384, 473
 Hyperosmolality, 115, 148, 149
 Hypersulfatemia, 442
 Hypertension, 391. *See also* Blood
 pressure; Cardiovascular disease
 caffeine and, 134
 children, 386
 defined, 473
 and diuretics, 227, 241
 drug therapy thresholds, 325
 guidelines for prevention and
 management, 378
 interactions of electrolytes and, 229
 intervention studies, 284-287
 plasma renin activity, 284-287
 prevalence, 354
 prevention of, 197, 201, 203, 208-
 211, 351-357, 378
 and renal disease, 325-326, 392
 sodium chloride and, 136, 195, 197,
 201, 203, 208-211, 271, 282, 283,
 301, 351-357, 380, 382, 391, 455
 Hypertension Prevention Trial, 336-
 337, 355, 356-357
 Hyperthermia, 111
 Hyperthyroidism, 442
 Hypoaldosteronism, 243, 301
 Hypocalciuria, 222, 229, 230
 Hypochloremia, 280, 299

Hypocitraturia, 224-225
 Hypohydration, 79, 473
 Hypoinsulinemia, 243
 Hypokalemia, 8, 38, 186, 192, 194-195,
 227, 228, 238, 239, 241, 249, 280,
 473
 Hyponatremia, 74, 161-164, 281, 299,
 300, 301, 315, 473
 Hyporeninemia, 243
 Hypotension, 136, 300
 Hypovolemia, 98, 105, 115, 119
 Hypoxia, 80, 83, 132

I

Indicators of nutrient adequacy. *See also*
 *specific indicators, nutrients,
 and life stages*
 methodological considerations, 31,
 42
 risk reduction-based, 28-29
 Infants, ages 0-12 months. *See also*
 Formulas, infant; Human milk
 ages 0 through 6 months, 29, 30,
 43-44, 90, 141, 142, 159, 231,
 232, 304, 305
 ages 7 through 12 months, 29, 30-
 31, 44, 90, 141-142, 159, 231-232,
 304, 305, 526
 AIs, 27, 29, 30, 43-44, 140-142, 231-
 232, 303-305, 455
 Bartter's syndrome, 303
 blood pressure, 239, 384-385
 bottle-fed, 90
 chloride deficiency, 280
 cystic fibrosis, 303
 dehydration, 384
 diarrhea, 437
 dietary intakes 30, 31, 43, 141-142,
 304, 526
 extrapolation of data from adults
 to, 44, 45
 extrapolation of data from younger
 to older infants, 44-45
 growth, 29, 44, 87, 301-303, 481
 hematuria, 280

hyperal...
 hyperch...
 hypoalc...
 hypoka...
 hypona...
 ileostor...
 low bir...
 metabo...
 method...
 45
 milk co...
 newbo...
 plasma...
 potass...
 252
 preter...
 pylori...
 recon...
 43
 refere...
 renal...
 sodiu...
 38
 solid...
 30
 speci...
 sulf...
 ULs,...
 wate...
 3
 weig...
 Insensi...
 Institut...
 Insulin...
 pot...
 ;
 resi...
 sod...
 an...
 Inter...
 an...
 an...
 pc...

INDEX

- 4-195,
9, 280,

299,

. See
ients,

ons, 31,

Also
in milk
9, 30,
231,

29, 30-
231-232,

42, 231-

35

141-142,
1 adults
1 younger
3, 481
- hyperaldosterone, 280
hyperchloremia, 302, 303
hypoaldosteronism, 301
hypokalemia, 280
hyponatremia, 162, 384
ileostomies, 301-302
low birth weight, 141, 301
metabolic acidosis, 280, 302
methodological considerations, 43-
45
milk consumption, 27, 141-142, 384
newborn, 59, 75, 90
plasma renin, 280
potassium, 44, 231-232, 239, 249,
252, 526
preterm, 301
pyloric stenosis, 303
recommended food sources, 29-30,
43, 44, 384
reference weight
renal disorders, 303
sodium and chloride, 44, 301-306,
384-385, 526
solid foods 30, 31, 44, 141, 231, 301,
304, 526
special considerations, 140-141
sulfate, 433, 436-437, 441
ULs, 249, 252
water, 75, 87, 90, 140-142, 159, 162,
384, 526
weight gain, 301
Insensible water losses, 83-85, 140
Institute of Medicine, 43, 44
Insulin
potassium and, 188, 194, 236-237,
243
resistance, 12, 38, 270, 275, 283,
292-293, 300
sodium chloride and, 12, 270, 275,
283, 292-293, 300
and water intake, 139
Interactions of dietary factors
and bioavailability, 60
and blood pressure, 388-390
potassium, 191, 195-197, 201, 203,
208-211, 218, 222, 224-225, 228-
230
sodium chloride, 195-197, 222, 224-
225, 273, 298-299, 323, 388-390
water, 133-136, 144-145
International Atomic Energy Agency,
22, 51
Intersalt study, 136, 197, 198-201, 327,
328, 350, 360-361, 373, 390
Intervention studies
blood pressure, 200-212, 325, 329-
351, 546-557
bone demineralization prevention,
219, 221-222
calcium, 370-371
cardiovascular diseases, 364, 367,
368-369
design features, 556-557
meta-analyses, 201-204, 205-206,
212, 282, 283, 325, 350-353
plasma renin activity, 284-287
potassium, 200-212, 219, 221-222
sodium and chloride, 202-203, 282,
283, 329-351, 364, 367, 368-371,
546-557
Iodine, 317-318
Iron, 30, 440, 480, 481
- J**
- Joint National Committee on
Prevention, Detection,
Evaluation, and Treatment of
High Blood Pressure, 378
- K**
- Kallikrein-kinin system, 273, 274
Ketoaciduria, 136
Ketosis, 135, 240
Kidney stones, 38. *See also* Renal
function
calcium and, 122, 123, 223, 372,
374-377
interactions of electrolytes and, 229
meat intake and, 224
potassium and, 8, 38, 186, 187, 189,
194, 222-225, 228, 229, 230, 231,
233, 234, 235, 240, 372

- sodium chloride and, 223-224, 372, 374-377
water consumption and, 122-123
- L**
- Lactation. *See also* Breastfeeding;
Human milk
adolescents, 153, 316, 383
AIs, 153, 239-240, 316
calcium, 33
derivation of DRIs for, 33, 46
hydration status, 153
potassium, 46, 239-240, 252-253
renal function, 153
sodium and chloride, 46, 304, 305,
316, 382-383
sulfate, 438
ULs, 252-253
water, 46, 153, 161
- Lanthionine, 430
- Left ventricle hypertrophy, 283, 358,
365-369, 377, 395
- Leukemia, 243
- Life-stage groups. *See also* Adolescents;
Adults; Children; Infants;
Toddlers
body water by, 77-78
categories, 29-33
chloride, 12-13
intakes by, 5, 10, 494-517
potassium, 10, 231-247, 249, 252-
253, 504-509, 516-517
serum osmolality by, 94, 95, 534-536
sodium and chloride, 12-13, 301-
318, 373, 376-387, 510-513, 516-
517, 560-563
sulfate, 430, 433-437
and toxicological sensitivities, 59
water, 5, 6-7, 77, 140-157, 159-160,
161, 494-503, 518-525, 528-529,
534-536
weights and heights, reference, 482
- Lithium, 140
- Liver function, 59, 121
- Low-carbohydrate, high-protein diets,
135, 240-241, 369
- Low-density lipoprotein cholesterol,
292, 294-295
- Lowest-Observed-Adverse-Effect Level
(LOAEL)
defined, 56-57, 473
identification of, 66, 69-70
intake data and, 72
sodium and chloride, 377-379, 380
and UL derivation, 57, 68, 69
- Lupus erythematosus, 252
- M**
- Macronutrients, 85, 135-136, 144-145.
See also Carbohydrate; Protein,
dietary
- Magnesium, 78, 201, 231, 309, 388,
389, 436
- Magnesium sulfate (Epsom salts), 426-
427, 436, 438-439
- Memory, 106-107
- Men
athletes, 127
gastric cancer, 373
heat capacity, 83
hydration of fat-free mass, 76-77
performance effects of dehydration,
105-107
plasma osmolality, 93
sodium, 322
urine osmolalities, 82
water intakes, 103
water requirements, 87, 88, 90, 91,
93, 127
- Metabolic acidosis, 194, 221, 228, 229,
240, 243, 274, 280, 303, 318, 438-
439
- Metabolic water production, 85-86, 140
- Metabolic weight ratio method, 44-45
- Metabolism
acid-base balance, 189-190, 224-225,
274
hydration status and, 110
potassium, 188-189

INDEX

- pregnancy and, 33, 59
 sodium and chloride, 272-274
 sulfate, 426-427
 water production and losses, 81, 83,
 85-86, 102, 140-141
- Methionine, 13, 27, 424, 425, 426, 427,
 429, 430, 432
- Methodological issues. *See also* Data
 and database issues; Indicators of
 nutrient adequacy
 AI derivation for infants, 43-45
 in balance studies, 39, 151
 in blood pressure studies, 289, 328,
 385
 body weight measurement, 101-102
 confounding and bias, 40, 101-102,
 105, 201, 326, 328, 367, 378
 data sources, 2-3, 38-43, 53, 326
 in dietary intake estimates, 40, 47,
 134, 145, 224, 245, 326, 358, 359,
 394, 450-451, 467
 epidemiological evidence, 39-40
 extrapolation from animal studies,
 38, 53, 61-62, 63-64, 65, 68, 69,
 564, 565, 566
 extrapolation from other age
 groups, 24, 31, 33, 42, 44-46, 69,
 233, 237
 factorial approach, 25, 480-481
 generalizability of studies, 39, 41,
 66-67
 human feeding studies, 38-39, 556
 557
 in hydration studies, 101-102, 116,
 151
 interactions of dietary factors, 201
 intervention studies, 329, 344-345,
 367, 556-557
 Monte Carlo approach, 25-26, 481
 in nutrient intake estimates, 40, 46-
 47
 observational studies, 38, 39-40, 61,
 326-329, 378
 pregnant and lactating women, 46,
 151
 randomized clinical trials, 40-41
 in risk assessment, 53, 61-62, 63-64,
 67, 564-567
 serum and plasma osmolality
 determinations, 95
 supplementation trials, 41
 weighing the evidence, 41-42, 61
- Methylsulfonylmethane, 431
- Methylxanthines, 133
- Military personnel
 heat exhaustion, 115, 121
 sodium requirements, 485-493
 water balance, 81, 84-85, 128, 129,
 130, 163, 485-493
- Mineralocorticoid receptor-mediated
 exchange, 273
- Mineralocorticoids, 189, 194, 238
- Mitral valve prolapse, 126
- Monte Carlo simulation, 25-26
- Mood, 106
- Motor control, 105-108
- Mountain sickness, 132
- Multiple Risk Factor Intervention
 Trial, 364
- Muscle catabolism, 38, 162, 274
- Muscle weakness, 8, 110, 116-117, 186,
 194, 236
- Myocardial infarction, 283, 358, 359,
 365
- N
- N-acetyl-L-cysteine, 430
- National Food Consumption Survey,
 86, 157, 158, 474
- National Health and Nutrition
 Examination Survey I,
 Epidemiological Follow-up
 Study, 359, 364
- National Health and Nutrition
 Examination Survey II, 45
- National Health and Nutrition
 Examination Survey III, 4-5, 34,
 46, 47, 48, 94, 95, 142, 143, 144,
 145, 153, 154, 158, 160, 161, 196,
 200-201, 216-217, 218, 245, 247,
 320, 322, 372, 394, 432, 481, 494-
 517, 534-545, 558-563

Nephrosclerosis, 326
 Net endogenous acid production, 219
 No-Observed-Adverse-Effect Level (NOAEL)
 defined, 56, 474
 identification of, 66, 69-70
 intake data and, 72
 and UL derivation, 57, 68, 69,
 379
 uncertainty factor, 57, 67, 68
 Nonsteroidal anti-inflammatory agents, 242, 243
 Nurses' Health Study, 198-199, 214-
 215, 218, 223, 224
 Nutrient intakes. *See also* Dietary
 intakes
 assessment of, 17-19, 70, 450-453
 biomarker measures, 40
 calculation of, 46-47
 chronic intakes above the UL, 70-71
 methodological considerations, 40,
 47
 Nutrient-nutrient interactions. *See also*
 Interactions of dietary factors
 adverse, 51
 Nutrition Canada Survey, 482, 483

O

Obesity and overweight, 40, 240, 364,
 365, 366, 390, 391-392, 450,
 482
 Observational studies. *See also*
 Epidemiological studies
 blood pressure, 197-200, 326-329
 methodological issues, 39-40, 326-
 329
 relevance, 39, 61
 sodium and chloride, 326-329
 Oncotic pressure, 79
 Orthostatic tolerance, 119
 Osmoreceptors, 104, 148
 Osteoarthritis, 429, 431
 Osteoporosis, 126-127, 189, 229, 377
 Oxalate, 122

P

Phosphate balance, 188, 219, 221
 3'-Phosphoadenosine-5'-
 phosphosulfate, 13, 424, 426,
 428, 429, 430, 431
 Phosphorus, 122
 Physical exercise and activity
 aerobic exercise, 108-110
 anaerobic exercise, 110, 114
 and body weight, 102, 110
 cardiovascular responses to, 119-
 120, 323
 children, 45, 110
 and core body temperature, 110,
 111, 114, 115, 132
 cystic fibrosis patients, 300
 endurance exercise, 110, 112-113,
 115, 118, 162, 163
 gastric emptying rate and, 131-132
 and heat strain, 6-7, 84, 102, 104,
 106, 110, 111, 114-117, 127-132,
 163, 164, 293, 296-298
 hydration status and, 97, 108-110,
 112-113, 114, 116-117, 163
 hyperhydration and, 117-118
 hypothermia of, 111
 leisure time, 154, 155, 537-545
 and plasma volume, 97
 and potassium, 225-227
 and pulmonary function, 372
 recommended, 145
 and salivary osmolality, 101
 and sodium, 115, 277
 and sodium chloride, 11, 14, 115,
 270, 277, 293, 296-298, 300, 308,
 317, 372, 485-493
 and sweating rates, 6-7, 154-156
 and thirst, 104
 and urine output, 83, 163
 and water losses and requirements,
 4, 6-7, 14, 74, 78, 80, 83, 84, 85-
 86, 88-89, 127-132, 144, 154-157,
 160, 162, 163, 164, 537-545
 Physical fitness, 92, 98, 109, 114, 127,
 129

Plasma
 aldo
 alka
 argi
 bica
 chlo
 cho
 osm

 pot

 pro
 rei

 soc
 vo

Polic
 Poly
 Potas
 al
 as

 a

 a

- Plasma
 aldosterone, 275, 277, 311, 314
 alkalinity, 274
 arginine vasopressin, 139, 148, 315
 bicarbonate, 190, 194, 221, 224, 238
 chloride, 194
 cholesterol, 283
 osmolality, 4, 92-94, 100, 102, 104,
 115, 139, 151-152
 potassium concentration, 188, 189,
 194, 226, 236, 237, 238, 248
 protein, 92, 132
 renin activity, 12, 275, 280, 281-287,
 291, 311, 314, 315, 359
 sodium, 95-97, 164, 194, 281, 315
 volume, 37, 97-98, 102, 104-105,
 119, 132, 150, 151, 272, 275, 277,
 281, 292, 300, 310, 313
- Police recruits, 121
- Polyuria, 151
- Potassium
 absorption and metabolism, 188-189
 and acid-base balance, 8, 186-187,
 189-190, 194, 221, 224-225, 228,
 229, 240, 459
 adolescents, 232-234, 239, 240, 249,
 252
 adults (19-50 years), 32, 191, 225,
 226, 228, 234-235, 245, 249, 323,
 530-531
 adverse effects of overconsumption,
 14-15, 187-188, 247-254, 459; *see also* Hyperkalemia
 AIs, 9, 10, 187, 231-240, 379, 454,
 456, 458-459
 and aldosterone, 189, 194, 238-239,
 243
 animal studies, 213, 236
 assessing and planning intakes, 458-
 459
 balance studies, 191-192, 193
 beta-adrenergic blockade, 236, 237,
 243
 bicarbonate precursors, 8, 186, 188,
 240-241, 242, 244, 458
 and blood pressure, 8, 9, 186, 187,
 194, 195-212, 213, 218, 228, 229,
 230-231, 232-233, 234, 235, 237,
 239, 241, 298, 330-345, 347, 388-
 389
 and bone mineral density, 8, 38,
 186, 187, 189, 190, 194, 219-222,
 228, 231, 233, 234, 235, 240
 and calcium balance, 189, 190, 194,
 218, 219, 221, 222, 224, 228, 229,
 230, 240
 and cardiac arrhythmias, 8, 14, 38,
 186, 194, 227, 242, 248-249
 and cardiovascular disease, 8, 186,
 195, 213-219, 241, 323, 354
 children, 45, 223, 225, 232-233, 234,
 237, 249, 252, 323
 and chronic disease prevention,
 194, 213-219
 and coronary heart disease, 213,
 216-217, 218, 354
 cyclo-oxygenase-2 inhibitors and,
 242, 243
 DASH diet, 348-349, 355
 deficiency, 192-193, 195, 222, 224,
 227, 228, 233; *see also*
 Hypokalemia
 dietary fiber and, 191, 201
 diuretics and, 188, 194-195, 227,
 239, 241, 242, 243, 249, 252-253,
 458
 dose-response assessment, 212, 249-
 254
 epidemiological studies, 197-200,
 212, 214-217, 219, 220-221, 222-
 224, 225, 234
 factors affecting requirements, 225-
 231, 458-459
 fecal losses, 189, 191
 fetal accretion, 237-238
 food sources of, 8-9, 186, 187, 188,
 192, 200-204, 212, 242, 244-245,
 249, 459
 forms of, 188, 191, 203, 228, 231,
 235, 247, 249

- function, 8, 37-38, 186, 188
 gastrointestinal discomfort, 14, 247-
 249, 252
 gender differences, 192, 504-509,
 516-517, 530-531, 558-559
 and glucose intolerance, 8, 186, 194
 hazard identification, 247-249
 heat exposure and, 225-227
 heparin and, 242, 243
 indicators of adequacy considered
 for, 8-9, 10, 190-195
 infants, 44, 231-232, 239, 249, 252,
 526
 and insulin, 188, 194, 236-237, 243
 intakes, 9, 10, 44, 48, 187, 192, 193,
 194, 197, 202, 204, 206, 208, 210,
 232, 234, 242, 245-247, 309, 504-
 507, 516-517, 526, 530-531
 interactions with other dietary
 factors, 191, 195-197, 201, 203,
 208-211, 222, 224-225, 228-230
 intervention studies, 200-212, 219,
 221-222
 and kidney stones, 8, 187, 38, 186,
 189, 194, 222-225, 228, 229, 230,
 231, 233, 234, 235, 240, 372, 459
 lactation, 46, 239-240, 252-253
 by life-stage group, 10, 231-247, 249,
 252-253, 504-509, 516-517, 558-
 559
 low-carbohydrate, high-protein
 diets, 240-241
 mineralocorticoids and, 189, 194,
 238
 and muscle weakness, 8, 186, 194,
 236
 nonsteroidal anti-inflammatory
 agents and, 242, 243
 older and elderly adults (51+ years),
 46, 188, 213, 236-237, 323, 530-
 531
 and osteoporosis, 189, 229
 and phosphate balance, 219, 221
 physical activity and, 225-227
 plasma concentrations, 188, 189,
 194, 226, 236, 237, 238, 248
 pregnancy, 46, 237-239, 245, 247,
 252, 253
 protein (dietary) interactions, 8,
 187, 189, 190, 219, 224
 and pulmonary function, 225
 race/ethnicity and, 9, 187, 195-197,
 202-203, 212, 218, 230-231, 234,
 245, 247, 506-509
 and renal function, 190, 213, 229,
 236, 239, 242, 243, 253, 458
 research recommendations, 254,
 466, 468
 salt sensitivity and, 8, 9, 38, 186,
 187, 194, 195-197, 228, 230-231,
 234, 235
 salt substitutes, 15, 242, 245, 248,
 249, 252-253, 254
 serum, 8; 186, 192-194, 197, 226-
 227, 238, 241, 252-253
 sickle cell anemia and, 239
 sodium chloride and, 190, 191, 195-
 197, 202-212, 222, 223-225, 228-
 231, 233, 235, 238, 273, 298-299,
 323, 329, 330-345, 347, 354, 372,
 379, 388-389, 516-517
 special considerations, 188, 237,
 240-242, 253-254
 and stroke, 8, 186, 194, 213, 214-
 217, 218, 219, 234
 supplements, 15, 187, 188, 195, 196,
 200, 201, 204-211, 212, 213, 218,
 219, 221, 222, 225, 227, 230, 233,
 241, 242, 245, 247, 249, 252, 299,
 458
 sweat losses, 189, 225-226, 227
 ULs, 14-15, 249-253
 and urinary citrate, 8, 186, 188, 224-
 225, 228, 240
 urinary excretion, 189, 191, 192,
 197, 202-203, 205, 206, 207, 209,
 211, 212, 225, 227, 230, 238-239,
 241, 247, 248, 249, 250-251, 331,
 333, 335, 337, 339, 341, 343, 345,
 347
 water balance and, 78, 226, 238-239

Potassium bicarbonate, 188, 190, 194, 195, 196, 210-211, 213, 219, 221, 222, 224, 228, 230, 234, 298, 459
Potassium chloride, 188, 194, 201, 204, 211, 212, 213, 221, 222, 228, 230, 236, 245, 247, 248, 254, 298
Potassium citrate, 188, 203, 210-211, 213, 221-222, 224-225, 234
Potassium sulfate, 426
Pregnancy. *See also* Lactation
 accretion of electrolytes, 237-238, 313-314
 adolescents, 152, 239, 383
 AIs, 33, 46, 151-152, 237-239, 313-316
 alkalemia of gestation, 238
 animal studies, 437-438
 balance studies, 314
 bicarbonaturia, 238
 blood pressure, 239, 382, 383
 body water, 151-152, 313
 diabetes insipidus, 152
 energy intake, 315
 hydration status, 151-152
 hyponatremia, 315
 kaliuresis, 238-239
 plasma osmolality, 151-152
 potassium, 46, 237-239, 245, 247, 252, 253
 pre-eclampsia and eclampsia, 239, 245, 253, 382, 438, 439
 renal function, 151, 152, 313, 315
 renin-angiotensin-aldosterone system, 314-315
 salt wasting, 314, 382
 sickle cell anemia, 239
 sodium and chloride, 46, 151, 238, 313-316, 322-323, 382-383
 sulfate, 429-430, 437-438, 439
 thirst, 151
 ULs, 59, 252, 382-383
 vomiting, 315
 water, 59, 151-152, 161
 weight, 151, 313-314
Progesterone, 238, 253, 315
Prostaglandins, 274, 381

Protein, dietary
 and acid-base balance, 224
 animal sources, 189-190, 224
 deficiency, 429
 intake, 24, 46, 98, 135, 144-145, 309;
 see also Low-carbohydrate, high-protein diets
 metabolism, 425, 427
 plasma levels, 92
 potassium interaction, 8, 187, 189, 190, 219, 224
 serum levels, 78, 292
 and sulfate, 425, 427, 429, 442
 and water consumption, 135
Psychogenic polydipsia, 14, 161, 162-163, 474
Puberty/pubertal development
 age at onset, 31, 483
 racial/ethnic differences, 31-32
 and sweating rate, 156
Pulmonary function, 225, 372, 377
Pyridinoline, 219

R

Race/ethnicity
 and blood pressure, 348, 380, 387, 388
 and potassium, 9, 187, 195-197, 202-203, 212, 218, 230-231, 234, 245, 247, 506-509
 and pubertal development, 31-32
 sodium, 16, 283, 348, 380, 512-513
 and water consumption, 141
Rancho Bernardo Study, 213, 214-215
Randomized clinical trials, 40-41
Recommended Dietary Allowance (RDA)
 AIs compared, 27
 applicable population, 23
 coefficient of variation, 24, 480
 criteria used to derive, 22
 defined, 3, 22, 23, 451, 474
 derivation, 3, 24
 EAR and, 23, 24-26, 480
 method used to set, 24-26

- | | | |
|--|--|---|
| <p>replacement with DRIs, 1, 449</p> <p>uses, 18-19, 23, 27, 451-452, 462-463</p> <p>Recommended Nutrient Intakes (RNI), 1, 449, 478</p> <p>Reference weights and heights</p> <ul style="list-style-type: none"> new, 34 use of, 33, 481-483 <p>Renal disease, 16, 139, 241, 243, 253, 271, 272, 310, 323, 325-326, 377, 380, 392</p> <p>Renal failure, 121, 162, 442</p> <p>Renal function. <i>See also</i> Kidney stones</p> <ul style="list-style-type: none"> BUN and, 98 concentrating ability, 147-148, 151 and dehydration, 98, 99, 139, 148, 152 diluting ability, 149, 151 incomplete syndrome of renal tubular acidosis, 229, 239, 243 lactation, 153 magnesium and, 436 in older adults, 32, 59, 147-149, 310-312 potassium and, 190, 213, 229, 236, 239, 242, 243, 253 pregnancy, 151 sodium chloride and, 148, 281, 303, 310-312, 313, 315 water consumption and, 74, 139, 147-149, 162, 163 weight and, 390 <p>Renin activity, 281-287</p> <p>Renin-angiotensin-aldosterone system, 94, 105, 273, 287, 291, 311, 314-315, 367, 381, 390, 391-392, 393</p> <p>Requirement, defined, 21-22</p> <p>Research recommendations, 19-20</p> <ul style="list-style-type: none"> approach to setting, 465-466 chronic disease relationships to intakes, 467-468 dietary intake assessment, 467 major knowledge gaps and, 466-467 potassium, 254, 466, 468 priorities, 468-470 sodium and chloride, 272, 395-397, 466, 467-468 | <p>sulfate, 443, 468</p> <p>water, 165-166, 468</p> <p>Respiratory water losses, 80-81, 102, 132-133</p> <p>Rhabdomyolysis, 121, 162, 243, 474</p> <p>Risk assessment models. <i>See also</i> UL modeling</p> <ul style="list-style-type: none"> application to nutrients, 28, 57-61 basic concepts, 52-53 bioavailability considerations, 60-61 defined, 52, 474 EPA guidelines, 566 and food safety, 28, 52-57 nutrient interactions, 60, 62 process, 54-55 sensitivity of individuals, 59-60, 64-65 thresholds, 55-57 uncertainties, 52, 53, 564-567 <p>Risk characterization</p> <ul style="list-style-type: none"> components of, 54, 55 defined, 52-53, 474 sodium and chloride, 394 sulfate, 442-443 water, 165 <p>Risk management, 53, 55, 71, 475, 566, 567</p> <p>Rotterdam Study, 200-201</p> | <p>S</p> <p>S-methylmethionine, 431</p> <p>Saliva specific gravity, 100-101</p> <p>Salt resistance, 287, 292, 388</p> <p>Salt sensitivity, 8, 9, 38, 186, 187, 194, 195-197, 228, 230-231, 234, 235, 271, 287, 311, 380, 381-382, 387-388, 389, 391, 392, 393, 475</p> <p>Salt substitutes, 15, 242, 245, 248, 249, 252-253, 254</p> <p>Salt wasting, 314, 382, 393</p> <p>Schizophrenia, 162</p> <p>Scottish Heart Health Study, 200-201, 216-217, 218, 327, 362-363, 364</p> <p>Sensitive subpopulations. <i>See</i> Special considerations</p> |
|--|--|---|

Serum

aldosterone, 315
arginine vasopressin, 148
bicarbonate, 240
creatinine, 242
glucose, 293
insulin, 293
osmolality, 4, 5, 94-95, 135, 137,
148, 150, 534-536
osteocalcin, 221, 240, 369
potassium, 8, 186, 192-194, 197, 226-
227, 238, 241, 252-253, 558-559
protein, 79
sodium and chloride, 137, 163-164,
281, 315, 560-563

Sickle cell anemia, 239

Skin
blood flow, 114
burns, 78,

Sodium, forms of, 9, 274-275, 318, 319

Sodium and chloride. *See also Salt*

sensitivity
adolescents, 306-307, 316, 382-383,
385-387
adults (19-50 years), 11, 32, 148,
234, 270, 271, 276, 281-282, 307-
310, 316, 320, 322, 323, 373, 376-
381, 382-383, 532-533

adverse effects of overconsumption,
13, 15-16, 45, 270-271, 320, 323-
395

AIs, 11, 12-13, 45-46, 235, 270, 303-
307, 308, 310, 312, 316, 320, 379,
454, 455, 456, 459-461

and aldosterone, 277, 291, 311, 314,
315, 393

animal studies, 301, 302-303, 357-
358, 373

assessing and planning intakes, 459-
461

balance studies, 275-281, 301-302,
314

and blood pressure, 15-16, 195-197,
202-212, 228, 230-231, 270-271,
273, 275, 281-291, 300, 311-312,
323-357, 376-379, 382-394, 395,
460, 546-557

and bone mineral density, 190, 372,
374-375, 377, 395

and calcium excretion, 222, 299,
369-372, 374-375, 377, 388,
389

and cardiovascular disease, 12, 270,
283, 323-325, 357-365, 377, 378,
379, 385, 387, 395, 460

children, 45, 278-281, 306-307, 323,
385-387

and coronary heart disease, 283,
357-365, 377

critical endpoint, 376-377

and cystic fibrosis, 137-138, 300

data selection, 373, 376

dermal and sweat losses, 11, 137,
163, 164, 273, 275, 276-281, 293,
296-298, 300, 308, 312, 315, 317,
485-493

and diabetes, 16, 300-301, 380, 391-
392

diuretics and, 281, 283, 299, 311,
382, 461

dose-response assessment, 15-16,
345-346, 373-387, 394, 546-557

epidemiological studies, 283, 323-
324, 326-329, 358, 359, 368, 374-
377, 378, 381

factors affecting requirements, 293,
296-301

factors affecting ULs, 387-394

food sources, 304, 318-320

function, 11, 38, 269, 272, 459

and gastric cancer, 372-373, 377,
395

gender differences, 312, 322, 348,
369, 390-391, 510-513, 516-517,
532-533, 560-563

genetic factors, 16, 393-394

and glucose intolerance, 292, 296-
297; *see also Diabetes mellitus*

and growth, 301-303

hazard identification, 323-373

and hydration status, 94, 95-97, 296,
301, 310

hyperchloremia, 302

- and hypertension, 136, 195, 197, 201, 203, 208-211, 271, 282, 283, 301, 351-357, 380, 382, 391, 455
 and hypoaldosteronism, 301
 hypochloremia, 280, 299
 hyponatremia, 281, 299, 300, 301, 315, 461
 indicators considered for setting requirements, 9, 11-13, 275-293, 303-305, 306-312, 313-316, 466
 in infant formula, 301, 302, 303, 305-306, 432
 infants, 44, 301-306, 384-385, 526
 and insulin resistance, 12, 270, 275, 283, 292-293, 300
 intakes, 44, 46, 203, 212, 272, 276, 277, 281, 282, 285, 287, 304, 320-323, 330, 332, 334, 336, 338, 340, 342, 344, 347, 394-396, 455, 510-513, 516-517, 526, 532-533
 interactions with other dietary factors, 195-197, 222, 224-225, 273, 298-299, 323, 388-390
 intervention studies, 202-203, 282, 283, 329-351, 364, 367, 368-371, 546-557
 and iodine intake, 317-318
 and kidney stones, 223-224, 372, 374-377
 lactation, 46, 304, 305, 316, 382-383
 and left ventricle hypertrophy, 283, 358, 365-369, 377, 395
 by life-stage group, 12-13, 301-318, 373, 376-387, 510-513, 516-517, 560-563
 and lipid levels, 12, 270, 283, 292, 294-295, 308
 LOAEL/NOAEL, 377-379, 380
 and magnesium, 388, 389
 meta-analyses of studies, 292, 323-324, 350-351, 378, 391
 metabolism, 272-274
 older and elderly adults (51+ years), 11-12, 45-46, 148, 270, 271, 280-281, 283, 299, 301, 310-313, 323, 380, 381-382, 532-533
 physical activity and, 11, 115, 270, 277, 293, 296-298, 300, 308, 317, 372, 460, 485-493
 plasma concentration, 95-97, 164, 194, 281, 315
 and plasma volume, 277, 292, 300, 310, 313
 potassium and, 190, 191, 195-197, 202-212, 222, 223-225, 228-231, 233, 235, 238, 273, 298-299, 323, 329, 330-345, 347, 354, 372, 379, 388-389, 516-517
 predictions of requirements, 485-493
 pregnancy, 46, 151, 238, 313-316, 322-323, 382-383
 and pulmonary function, 372, 377
 race/ethnicity, 16, 283, 348, 380, 512-513
 and renal disease, 16, 325-326, 377, 380, 392
 and renal function, 148, 281, 303, 310-312, 313, 315
 and renin activity, 12, 275, 280, 281-287, 291, 314, 315, 359
 and renin-angiotensin-aldosterone system, 287, 291, 311, 314-315, 381, 393
 research recommendations, 272, 395-397, 466, 467-468
 risk characterization, 394
 serum concentration, 95-97, 137, 163-164, 281, 315, 560-563
 special considerations, 317-318
 and stroke, 283, 357-365, 377
 supplements, 301, 302, 338-339, 455
 temperature and, 293-298, 308, 317, 485-493
 and thirst, 103, 104, 149
 transport defects, 148
 ULs, 13, 15-16, 45, 270-271, 320, 323-395, 456
 uncertainty assessment, 379-380

- urinary excretion, 197, 203, 205, 206, 207, 209, 211, 212, 276, 277, 282, 285, 287, 295, 298-299, 302, 310, 314, 320, 322, 326, 328, 331, 333, 335, 337, 339, 341, 343, 345, 347, 349, 351, 358-359, 366, 368, 372
and water, 4, 74, 78-79, 115, 136, 148, 151, 162, 163-164, 281, 485-493
and weight, 301, 313, 314, 390
- Sodium bicarbonate, 78, 274-275, 302, 318, 319, 369
- Sodium citrate, 275, 318, 369
- Sodium sulfate, 426, 436
- Special considerations
adults, 154-155
children, 155
chronic diseases, 253-254
diuretics, 241
high-temperature environments, 154, 317
hyperkalemia predisposition, 241-242
hyperthyroidism, 442
identification of, 64-65, 69
infants, 140-141
iodine intake, 317-318
low-carbohydrate, high-protein diets, 240-241
physical activity, 154-155, 156, 317
potassium, 188, 237, 240-242, 253-254
problem pregnancy, 253
renal failure, 253, 442
sodium and chloride, 317-318
sulfate, 442
water, 154-157
- Spirolactones, 227
- Stroke, 8, 150, 186, 194, 213, 214-217, 218, 219, 234, 283, 323, 324, 325, 354, 357-365, 377
- Sulfate
and acetaminophen, 428, 429
adults, 428, 433-436, 440-441
animal studies, 437-438
- bioavailable, 431
data quality and completeness, 3, 4, 13, 27, 424, 430, 441
deficiency, 427-429
and diarrhea, 424, 427, 433-438, 440, 441
dose-response assessment, 438, 440-442
in drinking water, 13, 425, 430, 432, 433-435, 436-437, 438, 440, 442-443
factors affecting requirements, 429-430
fetal requirements, 429-430
function, 13, 37, 424, 425-426
and growth, 427-428, 429-430
hazard identification, 433-440
and hyperthyroidism, 442
indicators considered for estimating requirements, 429
infants, 433, 436-437, 441
intake, 427, 428, 433, 434-435
lactation, 438
by life-stage group, 430, 433-437
and metabolic acidosis, 438-439
metabolism, 425-427
and osteoarthritis, 429, 431
pregnancy, 429-430, 437-438, 439
and renal failure, 442
research recommendations, 443, 467, 468
risk characterization, 442-443
sources, 4, 13, 27, 37, 424, 425, 426, 428, 430-433
special considerations, 442
supplements, 438, 439
and ulcerative colitis, 424, 439-440, 441
ULs, 16, 424, 433-443
- Supplements, dietary
bioavailability considerations, 22, 60-61
calcium, 299, 389
clinical trials, 41
data sources on intakes, 453
doses, 28, 51-52, 58

- potassium, 187, 188, 195, 196, 200, 201, 204-211, 212, 213, 218, 219, 221, 222, 225, 227, 230, 233, 241, 242, 245, 247, 249, 252, 299
 sodium, 301, 302, 338-339, 455
 sulfate, 438, 439
 ULs and, 28, 51, 58, 59, 60-61
 usefulness of, 28
Sweat/sweating
 and body temperature, 114
 body water losses, 83-85, 105, 127, 154, 155-156, 163, 485-493
 and body weight changes, 101
 children, 155-156
 cystic fibrosis and, 300, 303
 electrolyte losses, 45
 environmental factors, 127, 128, 132, 154
 hyperhydration and, 116
 infants, 140
 mathematical modeling, 130-131, 485-493
 physical activity and, 6-7, 154-156
 potassium losses, 189, 225-226, 227
 pregnancy and, 315
 and sodium chloride, 11, 137, 163, 164, 273, 275, 276-281, 293, 296-298, 300, 308, 312, 315, 317, 485-493
 and thirst, 105
 and water needs, 6-7, 128, 154, 155, 163
Sympathetic nervous system activity, 273-274, 367, 390
- T**
- Taurine, 430, 431
Temperature. *See also Climate*
 core body, 110, 114, 115, 118, 121;
see also Thermoregulation
 and physical activity, 293-298
 and sodium chloride, 293-298, 308, 317, 485-493
 and water requirements, 80, 81
Theobromine, 133
Theophylline, 133
Thermoregulation, 79, 83-85, 110, 111, 115-117, 133
Thiamin, 426
Thirst
 defined, 102
 elderly adults, 149-150
 hydration status and, 86, 102-105, 149-150, 151
 infants, 140
 measurement of, 102
 osmotic threshold, 149
 perceptual factors, 102-104
 physiological triggers, 104-105, 137
 pregnancy and, 151
 sodium chloride and, 103, 104, 149
 and water consumption, 7, 74, 102-104
Toddlers, ages 1 through 3 years
 AIs, 233, 307
 chloride, 387
 energy intakes, 306
 indicators used to set AIs, 31
 potassium, 233
 sodium, 306, 307, 387
 ULs, 386-387
 water, 143, 159
Tolerable, defined, 27-28, 50
Tolerable Upper Intake Levels (ULs).
See also UL modeling
 applicable population, 50, 59-60
 defined, 3, 27-28, 50, 58, 475-476
 derivation of, 28, 45, 52-53, 56, 57-59, 65, 68-69, 380-381, 452
 for nutrition labels, 456
 potassium, 14-15, 249-253
 sodium and chloride, 13, 15-16, 323-395, 456
 sulfate, 16, 424, 433-443
 supplement use and, 28, 51
 uses, 18-19, 28, 51, 452-453, 455, 456, 462-463
 water, 14
Toxicity, mechanisms of action, 64
Trauma, 78

i, 110, 111,
102-105,
4
4-105, 137
3, 104, 149
7, 74, 102-
years
, 31
0
els (ULs).
0, 59-60
475-476
53, 56, 57-
, 452
3
, 15-16, 323-
51
53, 455,
ion, 64

Trials of Hypertension Prevention, 336-337, 349, 355, 356-357, 391, 393, 475

Triamterene, 227, 243

U

UL modeling. *See also* Dose-response assessment; Risk assessment models
critical endpoint, 60, 65-66
data selection, 65-66, 373, 376
exposure assessment, 53, 63, 65
hazard identification, 61-65
mathematical models, 52
nutrient intake assessment, 70
risk characterization, 70-72
selection of UL
uncertainty assessment, 66-68, 379-380

Ulcerative colitis, 424, 439-440, 441

Uncertainties
approaches for dealing with, 56, 66-67, 564-567
assessment, 66-68, 379-380
case-by-case judgments, 566, 567
in data, 53, 56, 57
default options, 566, 567
dose-response assessment, 65, 66-68
extrapolation from one age group to another, 233
inferences from experimental animal studies, 53, 68, 564, 565
range of estimates applied to, 566-567
in risk assessment, 52, 53, 55, 67-68, 564-567
for sodium and chloride, 379-380

Uncertainty factors
defined, 56, 475
selection of, 66

Urea, 135, 151, 427, 429

Uric acid, 122

Urinary tract infections, 121-122. *See also* Bladder cancer

Urine/urinary
calcium excretion, 223, 224, 240
citrate excretion, 8, 186, 188, 224-225, 228, 240
color, 99
deoxypyridinoline, 219, 221
and hydration status, 82-83, 92, 99-101, 105, 148
hydroxyproline, 221
n-teleopeptide, 221
net acid excretion, 240
osmolality, 99-100, 121, 136, 139, 147, 149
potassium excretion, 189, 191, 192, 197, 202-203, 205, 206, 207, 209, 211, 212, 225, 227, 230, 238-239, 241, 247, 248, 249, 250-251, 331, 333, 335, 337, 339, 341, 343, 345, 347
pyridinoline, 219, 221
sodium excretion, 197, 203, 205, 206, 207, 209, 211, 212, 276, 277, 282, 285, 287, 295, 298-299, 302, 310, 314, 320, 322, 326, 328, 331, 333, 335, 337, 339, 341, 343, 345, 347, 349, 351, 358-359, 366, 368, 372
specific gravity, 99-100, 101, 133
sulfate, 427
volume, 82, 83, 99, 122, 136, 139
water losses, 81-83, 102, 105, 134, 140

Urolithiasis, 221-222

U.S. Army Research Institute of Environmental Medicine model, 485-493

U.S. Department of Agriculture, 47, 48, 141

U.S. Department of Health and Human Services, 47
Office of Disease Prevention and Health Promotion, 1

U.S. Environmental Protection Agency, 433, 440, 442, 566

U.S. Food and Drug Administration, 319

V

Vagal system, 105, 124
Vasopressinase, 152
Vegetarians, 354
Vitamin E, 440
Volume receptors, 104-105
Vomiting, 94, 280, 303, 315

W

Water consumption. *See also* Body water; Dehydration; Drinking water; Hyperhydration; Hydration status
adolescents, 142-144, 152, 153, 155-157, 159-160, 540-545
adults (19-50 years), 5-6, 87-88, 144-147, 154-155, 157-158, 159-160, 161, 540-545
adverse effects of overconsumption, 14, 74, 154-165
AIs, 4, 5, 6-7, 73, 140-157, 453-454, 456-458
altitude exposure and, 80, 132-133
assessment of intakes, 79
balance studies, 86-89, 93, 140, 142
from beverages, 5, 73, 86, 145, 146-147, 157, 158, 160, 161, 500-501, 522-523
and bladder cancer, 124-125
and bladder lesions from overconsumption, 164
Canadian, 6, 74, 160, 528-529
children, 45, 87, 142-143, 155-157, 159-160, 164, 538-539
in cold climates, 89, 132-133
and colon cancer, 124
cystic fibrosis and, 137-138, 163
diabetes mellitus and, 136-137, 139
diuretics and medication use and, 7, 139-140, 458
dose-response assessment, 154-165
from drinking water, 73, 86, 158, 161, 498-501, 520-523
environmental factors, 4, 74, 88, 89, 90, 127-133, 144

exposure assessment 165
factors affecting, 127-140, 144
flavor preferences and, 103-104
from food, 5, 6, 73-74, 86, 145, 146-147, 152, 158, 160, 161, 457, 502-503, 524-525, 526
and gallstones, 124
gender differences, 87, 88, 90, 91, 93, 127, 154, 155, 159-160, 161, 457, 494-503, 518-525, 528-529, 538-545
hazard identification, 162-164
heat strain and, 89, 127-132
heat stress and, 89, 90, 105, 110, 118, 120-121, 131, 133, 157, 163, 485-493
in hot climates, 6, 74, 88, 164
hydration status and, 86, 92, 94-95, 102
and hyponatremia, 14, 161-164, 281
indicators of adequacy, 4-8, 122
from infant weaning foods, 526
infants, 87, 140-142, 162
intake data, 4-5, 48, 103, 157-161, 498-501, 502-503, 524-525, 526, 534-545
interactions of dietary factors, 133-136, 144-145, 457
and kidney stones, 122-123
lactation, 46, 153, 161
by life-stage group, 5, 6-7, 140-157, 159-160, 161, 494-503, 518-525, 528-529, 534-536
macronutrient intakes and, 135-136, 144-145, 457
methods for estimating, 86-90
older and elderly adults (51+ years), 147-150, 159-160, 161, 540-545
pathophysiological factors, 136-140
physical activity and, 4, 6-7, 14, 74, 80, 88-89, 127-132, 144, 154-157, 160, 162, 163, 164, 457, 485-493, 537-545
potassium excretion, 78, 238-239
pregnancy, 151-152, 161
protein intake and, 135

race/ethnicity and, 141
renal disease and, 139
and renal function, 74, 139, 147-149, 162, 163
research recommendations, 165-166, 466, 468
risk characterization, 165
and sodium chloride, 74, 136, 162, 163-164, 281, 485-493
special considerations, 154-157
therapeutic effects of, 122-123
thirst and, 7, 74, 102-104
total intakes, 4, 5, 7, 73, 86, 158, 159, 475, 494-497, 518-519
Weight. *See also* Obesity and
overweight; Reference weights
and heights
adjustment of AIs based on, 233
and blood pressure, 390, 394
body water and, 77, 78, 86-87
and cardiovascular disease, 323, 354
hydration status and, 101-102, 110, 151
and hypertension, 354
measurement confounding, 101-102
pregnancy, 151
rapid loss, 121, 125
sodium chloride and, 301, 313, 314, 390
WHO-Cardiac Study, 327
Wilson's disease, 430

Women
athletes, 127-128
BMI, 483
blood pressure, 390-391
bone mineral density, 219, 220-221, 222
calcium, 369
heat capacity, 83-84
high-protein diet, 369
hydration of fat-free mass, 76-77
hyponatremia, 162, 164, 299
perimenopausal, 219, 390
plasma osmolarity, 93
postmenopausal, 219, 222, 369, 390
potassium, 219, 236
sodium chloride, 322, 369
urinary tract infections, 121-122
water requirements, 88, 90, 91, 93, 121-122, 127-128
World Health Organization, 22, 44, 50-51, 56, 442

Y

Yanomamo Indians (Brazil), 11, 269, 276, 315, 322, 328, 350

Z

Zinc, 30